

Informazione Regolamentata n. 0957-45-2024	Data/Ora Inizio Diffusione 27 Agosto 2024 10:24:49	Euronext Milan
--	---	----------------

Societa' : DIASORIN

Identificativo Informazione
Regolamentata : 194938

Utenza - Referente : DIASORINN01 - Ulisse Spada - Valerio
Giovanni Vaccarone

Tipologia : 2.5

Data/Ora Ricezione : 27 Agosto 2024 10:24:49

Data/Ora Inizio Diffusione : 27 Agosto 2024 10:24:49

Oggetto : Communication on total amount of voting rights

Testo del comunicato

See attachment.

DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

Saluggia, August 27, 2024 – In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999 Diasorin (FTSE MIB: DIA) hereby communicates the total amount of the voting rights, together with the number of shares making up the share capital, as of August 26, 2024 (record date):

	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	88,351,178	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular dividend) Current coupon: no. 19	23,545,336	23,545,336	-
Ordinary shares with increased voting rights ISIN IT0005188385 (regular dividend) Current coupon: no. 19	32,402,921	62,805,842	-

It should be noted that no changes occurred with respect to the total amount of voting rights last disclosed on July 5, 2024.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo
Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.com

